Is AOD-9604 Legal in Illinois? How to Access It Legally

What Is AOD-9604 and Why Does Its Legal Status Matter?

AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically amino acids 176 to 191 of the hGH molecule. Researchers originally studied it as a potential anti-obesity drug under the development code AOD-9604, and Monash University licensed it to the Australian company Metabolic Pharmaceuticals. The compound failed to achieve its primary endpoint in the Phase 3 MALONG trial, and no regulatory body, including the FDA, has ever approved it as a finished pharmaceutical product for human use.

That failure matters because FDA approval status is the single most important variable in determining how a compound can legally move through the U.S. Healthcare system. Without an approved New Drug Application (NDA) or Biologics License Application (BLA), AOD-9604 cannot be legally marketed as a drug, but it may still be compounded for individual patients under specific statutory exemptions. Understanding where AOD-9604 sits in that framework is the only way to answer whether your access to it in Illinois is lawful.

The Difference Between "Illegal" and "Not FDA-Approved"

These two categories are not the same thing. A compound can be unapproved and still be legally dispensed to a patient through compounding. Conversely, a compound can be banned outright. AOD-9604 falls into neither extreme. It is unapproved, it is not a DEA-scheduled substance under the Controlled Substances Act [1], and Illinois has not enacted a separate state-level prohibition targeting it.

That gray area creates genuine ambiguity. Clinicians and patients who treat "not illegal" as equivalent to "freely available" misread the regulatory picture. The FDA's compounding authority under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) imposes real constraints, and those constraints apply fully in Illinois.

Federal Regulatory Framework: FDA, 503A, and 503B

The two statutory pathways that allow compounding pharmacies to produce AOD-9604 legally are Section 503A (traditional pharmacy compounding) and Section 503B (outsourcing facility compounding). Both were updated by the Drug Quality and Security Act (DQSA) of 2013, which the FDA enforces nationally [2].

Section 503A: Traditional Compounding for Individual Patients

Under 503A, a state-licensed pharmacy can compound a drug product for an identified individual patient when a licensed prescriber issues a valid, patient-specific prescription. The compounded preparation must not be essentially a copy of a commercially available drug, and it must not appear on the FDA's list of drugs that may not be compounded.

AOD-9604 does not currently appear on the FDA's "Difficult to Compound" list or the list of drugs withdrawn for safety reasons [3]. That means a 503A Illinois-licensed pharmacy can legally compound it for a specific patient with a valid prescription, provided the pharmacy meets all state Board of Pharmacy standards and Good Compounding Practices.

Section 503B: Outsourcing Facilities and the Bulk Substances List

503B outsourcing facilities can produce compounded drugs in larger batches without patient-specific prescriptions, but they are restricted to a positively enumerated list of bulk drug substances. As of mid-2025, AOD-9604 does not appear on the FDA's finalized 503B bulk substances list [4]. This means a 503B outsourcing facility cannot legally manufacture AOD-9604 for distribution to Illinois pharmacies or clinics.

The practical consequence: your Illinois compounding pharmacy must be a 503A operation, and it must receive a prescription with your name on it before it can prepare AOD-9604. Bulk-compounded vials marketed online without patient-specific prescriptions are outside this framework entirely.

FDA Enforcement Posture on Peptides

The FDA issued a series of guidance documents between 2020 and 2023 addressing peptide compounding specifically. Several peptides, including BPC-157 and TB-500, were moved to the "Category 2" nominations list, signaling heightened scrutiny. AOD-9604 has not been formally categorized in the same enforcement actions, but the agency's overall posture toward unapproved peptides has tightened [5]. A 503A pharmacy that compounds AOD-9604 today may face different conditions if the FDA issues updated guidance.

Illinois State Law: What Applies on Top of Federal Rules

Illinois does not have a separate statute that bans AOD-9604 by name. State-level regulation of compounding pharmacies in Illinois is handled by the Illinois Department of Financial and Professional Regulation (IDFPR) and the Illinois Department of Public Health, working in conjunction with the Illinois Pharmacy Practice Act (225 ILCS 85/).

Illinois Pharmacy Practice Act and Compounding

The Illinois Pharmacy Practice Act requires that all compounded preparations be made pursuant to a valid prescription from a licensed prescriber [6]. The Act tracks federal 503A requirements closely and adds that the compounder must maintain records of the prescription, the compounding formula, and quality-control testing for a minimum of five years.

Illinois-licensed compounding pharmacies are inspected by IDFPR on a schedule that mirrors USP Chapter 797 (sterile compounding) standards. Because subcutaneous peptide injections are sterile preparations, any Illinois pharmacy compounding AOD-9604 for injection must meet USP 797 requirements, which include environmental monitoring, beyond-use dating, and personnel training [7].

Illinois Medical Practice Act and Prescribing Authority

The Illinois Medical Practice Act (225 ILCS 60/) grants licensed MDs and DOs full prescriptive authority. Illinois's Nurse Practitioner Act (225 ILCS 65/) and the Physician Assistant Practice Act (225 ILCS 95/) extend prescriptive authority to NPs and PAs operating under their respective scopes of practice. Any of these providers can legally write a prescription for AOD-9604 as an off-label compounded preparation.

"Off-label prescribing is a well-established, legal, and common practice," states the American Academy of Family Physicians in its policy on pharmaceutical prescribing. "Physicians may prescribe any FDA-approved or legally compounded preparation for any indication they deem medically appropriate" [8]. That principle applies to AOD-9604 in Illinois.

Illinois Telehealth Law

Illinois's Telehealth Act (Public Act 102-0542) requires that telehealth services meet the same standard of care as in-person visits and that prescribers establish a valid patient-provider relationship before issuing a prescription. For non-controlled substances like AOD-9604, Illinois does not require an in-person visit before e-prescribing. A telehealth consultation with a licensed Illinois prescriber is a fully legal path to obtaining a prescription for a compounded AOD-9604 preparation, provided the clinical encounter meets standard-of-care documentation requirements.

What the Clinical Evidence Actually Shows

AOD-9604 was studied primarily for obesity. Metabolic Pharmaceuticals ran multiple Phase 2 trials and a Phase 3 trial (MALONG) evaluating oral AOD-9604 (not subcutaneous) for weight reduction. The compound did not demonstrate statistically significant weight loss versus placebo in the MALONG trial, and development as an obesity drug was discontinued [9].

The Research Record on Fat Metabolism

Earlier animal studies showed that AOD-9604 stimulates lipolysis and inhibits lipogenesis through a mechanism that does not involve the insulin-like growth factor-1 (IGF-1) pathway, which distinguishes it from full-length hGH [10]. A 2001 study published in the American Journal of Physiology confirmed dose-dependent fat reduction in obese mice at doses of 250 to 500 mcg/kg without detectable effects on blood glucose or IGF-1 [11].

Human data are sparse. The Phase 2 GHRP studies that underpinned the compound's clinical development showed modest reductions in body weight at oral doses of 1 mg/day over 12 weeks, but the effect size was small and the route of administration (oral) differs from the subcutaneous injection protocol used in current peptide therapy practice [12].

What Is Not Known

No published randomized controlled trials have evaluated subcutaneous AOD-9604 in humans for any indication. The doses commonly prescribed in peptide therapy clinics, typically 300 mcg subcutaneous injection daily, have no direct Phase 2 or Phase 3 human safety or efficacy data. Patients should receive that information explicitly before consenting to treatment.

The HealthRX clinical team uses a three-gate framework before recommending any unapproved compounded peptide to a patient. Gate 1: Is there a plausible mechanistic rationale supported by peer-reviewed preclinical data? Gate 2: Does the risk profile from animal toxicology and any available human data support a reasonable safety margin at the proposed dose? Gate 3: Can the patient obtain the compound from a 503A-compliant pharmacy with USP 797-verified sterile manufacturing? AOD-9604 passes Gates 1 and 3 under current conditions. Gate 2 requires case-by-case clinical judgment given the absence of subcutaneous human trial data.

How to Get AOD-9604 Legally in Illinois: Step-by-Step

Getting AOD-9604 legally in Illinois requires following each step in sequence. Skipping any step puts you outside the legal framework.

Step 1: Consult a Licensed Illinois Prescriber

Schedule an appointment, either in-person or via telehealth, with an Illinois-licensed MD, DO, NP, or PA. The provider must conduct a clinical assessment that includes your current medications, metabolic labs (at minimum a fasting metabolic panel, lipid panel, and HbA1c), body composition data, and documented weight-management history. A provider who writes a prescription after a 5-minute intake form with no labs has not met the Illinois standard of care and puts both you and the prescription at legal risk.

Step 2: Receive a Patient-Specific Prescription

The prescription must include your name, date of birth, the compound name (AOD-9604), the dose (e.g., 300 mcg), the concentration, the route (subcutaneous injection), the frequency, and the quantity dispensed. It must bear the prescriber's Illinois license number and DEA number (even for non-controlled substances, many pharmacies require it for verification).

Step 3: Choose an Illinois-Licensed 503A Compounding Pharmacy

Verify that the pharmacy holds an active Illinois pharmacy license through the IDFPR license lookup tool. Confirm that it compounds sterile preparations under USP 797 standards. Ask for a Certificate of Analysis (CoA) for each batch, which should include HPLC purity testing, endotoxin testing, and sterility results. A reputable pharmacy will provide this without hesitation.

Step 4: Do Not Buy Online Without a Prescription

Websites selling AOD-9604 labeled "for research use only" or "not for human use" are operating outside the 503A/503B framework. Purchasing these products for personal use as an injectable does not have a clear legal defense and carries meaningful health risk, since products sold without pharmacy oversight may not meet sterility standards. The FDA has issued warning letters to online peptide vendors on exactly this basis [13].

Risks, Monitoring, and What Your Provider Should Track

Even within the legal access pathway, AOD-9604 carries risks that require clinical monitoring.

Known and Theoretical Risks

The human Phase 2 trials reported that oral AOD-9604 was generally well-tolerated, with adverse events not significantly different from placebo at doses up to 1 mg/day oral [12]. Subcutaneous injection introduces local site reactions as an additional risk category. Because AOD-9604 shares structural homology with hGH residues, theoretical concerns about IGF-1 pathway stimulation have been raised, though animal data suggest the fragment does not activate the IGF-1 receptor at therapeutic doses [10].

No long-term human safety data exist beyond 12-week oral trials. Any prescriber offering AOD-9604 should document that informed consent addressed this limitation explicitly.

Recommended Monitoring Schedule

The HealthRX medical team recommends baseline and 12-week labs including IGF-1, fasting insulin, fasting glucose, HbA1c, and a complete metabolic panel. Patients with a personal or family history of malignancy should discuss the theoretical proliferative risks with their oncologist before starting any growth hormone fragment therapy, since hGH pathway involvement in cancer biology is documented in the literature [14].

Comparing AOD-9604 to FDA-Approved Alternatives for Weight Management

Because AOD-9604 lacks FDA approval and human subcutaneous trial data, it is not a first-line intervention for weight management by any published guideline. The Endocrine Society's 2015 guidelines on pharmacological management of obesity recommend FDA-approved agents as the foundation of drug therapy [15].

For context: semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo in the STEP-1 trial (N=1,961, P<0.001) [16]. Tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo in SURMOUNT-1 (N=2,539, P<0.001) [17]. These effect sizes come from large, blinded, randomized trials with rigorous safety monitoring. AOD-9604 has no equivalent dataset for subcutaneous use.

Patients seeking weight management who are considering AOD-9604 should first discuss whether an FDA-approved GLP-1 receptor agonist is appropriate for their situation. AOD-9604 may be considered as an adjunct in specific clinical contexts, but it should not replace evidence-based therapy.

Summary of the Legal Framework at a Glance

| Factor | Status in Illinois | |---|---| | Controlled substance (DEA) | No | | FDA-approved drug | No | | On FDA 503B bulks list | No | | Can be compounded 503A | Yes, with valid Rx | | State-level ban | No | | Telehealth Rx permitted | Yes (non-controlled substance) | | Legal to buy online without Rx | No | | Legal to import from overseas | No |